Charting a Pathway to Follow-On Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Charting a Pathway to Follow-On Biologics
Debates about science, manufacturing, and European regulations will shape the approval process for follow-on biologics in the United States.


Pharmaceutical Technology
Volume 33, Issue 6, pp. 36-42

Reactions to the bills

The Waxman bill enjoys the support of the Generic Pharmaceutical Association. It would enable FDA to take a case-by-case approach to approving these therapies. "We're interested in flexibility for good science rather than in a rigid, predetermined structure," says Marc Goshko, executive director of legal affairs at Teva Pharmaceuticals (North Wales, PA).

BIO supports the Eshoo bill. Merck recognizes the need for an abbreviated approval pathway for follow-on biologics. "There still remains a need for clinical studies to demonstrate safety, efficacy, and lack of deleterious immunogenicity for bio-similar products," says Cannon.

Conclusion

As science and manufacturing technologies improve, biopharmaceuticals will become easier to produce. An approval process for follow-on biologics in the US would help improve patients' health and make needed medicines more affordable. In the absence of international standards for follow-on biologics approval, Congress must create a regulatory pathway through legislation. At a minimum, an approval mechanism must ensure that follow-on products react in the human body the same way as their respective reference products, says Bill Haddad, CEO of Biogenerics (Brewster, NY). A pathway should also provide patent protection for innovators' products and allow patents to be challenged.

Despite ongoing debate, some believe that an approval pathway could be established soon. "It took us 35 years to reach Hatch–Waxman from the early efforts of Senator Estes Kefauver," says Haddad. "It won't take us that long to get a fair and equitable biotech law. When the dust settles, as it did following Hatch–Waxman, we will look back and wonder, 'What in the hell was all the fuss about?'"

References

1. FDA, "Generic Drugs: Questions and Answers," http://www.fda.gov/cder/consumerinfo/generics_q&a.htm, accessed Apr. 27, 2009.

2. World Health Organization, "WHO Informal Consultation on International Nonproprietary Names (INN): Policy for Biosimilar Products," http://www.who.int/entity/medicines/services/inn/BiosimilarsINN_Report.pdf, accessed Apr. 27, 2009

3. FDA, Guidance for Industry: Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process (Rockville, MD, June 2005) http://www.fda.gov/CbER/gdlns/ichcompbio.htm, accessed Apr. 30, 2009

4. D. McCormick, "Small Changes, Big Effects in Biological Manufacturing," Pharm. Technol. 28 (11), 16 (2004).

5. Biotechnology Industry Organization, "Why is Patient Safety a Concern in the Biosimilars Debate?" http://www.bio.org/healthcare/followonbkg/PatientSafety.asp/, accessed May 4, 2009

6. Code of Federal Regulations, Title 42, The Public Health and Welfare (General Services Administration, Washington, DC, 2003), sec. 262, http://www.fda.gov/opacom/laws/phsvcact/sec262.htm, accessed May 4, 2009.

7. Berlex v. FDA et al., US District Court for the District of Columbia, Oct. 7, 1996, http://www.fda.gov/ohrms/dockets/dailys/04/mar04/031904/80n-0208-ref0001-19-Tab-11-vol126.pdf, accessed May 15, 2009.

8. C. Webster et al., "Biologics: Can There Be Abbreviated Applications, Generics, or Follow-On Products?" Biopharm. Int. 16 (7), 28–37 (2003).

9. G. Perry, "Biosimilar Medicines: Towards Global Development and Monoclonal Antibodies," presented at the 7th EGA Annual Symposium on Biosimilar Medicines, London, Apr. 2009.

10. H.R.1427, "Promoting Innovation and Access to Life-Saving Medicine Act," US House, 111th Congress, 1st Session (Washington, DC), Mar. 11, 2009, http://thomas.loc.gov/cgi-bin/query/F?c111:1:./temp/~c111RCfWrl:e0:/, accessed May 5, 2009.

11. H.R.1548, "Pathway for Biosimilars Act," US House, 111th Congress, 1st Session (Washington, DC), Mar. 17, 2009, http://thomas.loc.gov/cgi-bin/query/F?c111:1:./temp/~c111S3Mkrr:e0:/, accessed May 5, 2009.


ADVERTISEMENT

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Source: Pharmaceutical Technology,
Click here